Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Simple stem cell production method shows promise in mice for treating IPF

Simple stem cell production method shows promise in mice for treating IPF

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Autoantibodies play major role in IPF patients with acute exacerbations

Autoantibodies play major role in IPF patients with acute exacerbations

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

New study describes way to regenerate lung tissue after injury

New study describes way to regenerate lung tissue after injury

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Researchers identify promising new approach to treat pulmonary fibrosis

Researchers identify promising new approach to treat pulmonary fibrosis

Study explores outcomes of lung transplantations after implementing need-based allocation system

Study explores outcomes of lung transplantations after implementing need-based allocation system

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award